Travere Therapeutics (TVTX) Non-Current Deffered Revenue (2021 - 2024)
Travere Therapeutics' (TVTX) quarterly Non-Current Deffered Revenue came in at $888000.0 in Q1 2024, down 89.88% YoY from $8.8 million in Q2 2023, and down 51.61% on a QoQ basis from $1.8 million in Q4 2023.
Travere Therapeutics (TVTX) Non-Current Deffered Revenue (2021 - 2024) Analysis & Trends
Travere Therapeutics (TVTX) has 4 years of Non-Current Deffered Revenue data on file, last reported at $888000.0 in Q1 2024.
- Quarterly Non-Current Deffered Revenue fell 89.88% year-over-year to $888000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $888000.0 (down 89.88% YoY) and the FY2023 annual result came in at $1.8 million, down 83.21% from the prior year.
- Non-Current Deffered Revenue eased to $888000.0 in Q1 2024, from $1.8 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $24.1 million in Q3 2021 to a low of $888000.0 in Q1 2024.
- A 4-year average of $11.6 million and a median of $10.9 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue slumped 46.36% — and 2024, when it tumbled 89.88%.
- Tracing TVTX's Non-Current Deffered Revenue over 4 years: stood at $20.4 million in 2021, then slumped by 46.36% to $10.9 million in 2022, then slumped by 83.21% to $1.8 million in 2023, then plunged by 51.61% to $888000.0 in 2024.
- The last three Non-Current Deffered Revenue figures came in at $888000.0 (Q1 2024), $1.8 million (Q4 2023), and $4.6 million (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 888,000.00 |
| Dec 31, 2023 | 1.84 Mn |
| Sep 30, 2023 | 4.57 Mn |
| Jun 30, 2023 | 6.79 Mn |
| Mar 31, 2023 | 8.78 Mn |
| Dec 31, 2022 | 10.93 Mn |
| Sep 30, 2022 | 12.92 Mn |
| Jun 30, 2022 | 16.24 Mn |
| Mar 31, 2022 | 19.67 Mn |
| Dec 31, 2021 | 20.38 Mn |
| Sep 30, 2021 | 24.08 Mn |